CV Sciences

CV Sciences is a pharmaceutical company specializing in the production, marketing and sale of cannabis-based products for various market sectors. It develops new therapeutic agents and invests in the scientific research required to achieve the universally recognized safe status of medical marijuana.
CV Sciences stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

CV Sciences balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

CV Sciences cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

CV Sciences multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

CV Sciences profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
CV Sciences assets
CV Sciences cash flows

CV Sciences shares

TickerNameTypeNominal valueISINPrice
CVSI:USCV SciencesCommon share-US1266541028$0.04
CV Sciences news
16.05.2022
CV Sciences' GAAP loss for 3 months of 2022 was $2.217 million, down 29.1% from $3.127 million in the prior year. Revenue decreased 8.2% to $4.447 million from $4.844 million a year earlier.
Source: {source} pictogram ir.cvsciences.com
Pictogram next
01.04.2022
CV Sciences' GAAP loss for 2021 was $15.554 million, down 30.2% from $22.284 million the previous year. Revenue decreased 17.9% to $20.048 million from $24.429 million a year earlier.
Source: {source} pictogram ir.cvsciences.com
Pictogram next
15.11.2021
CV Sciences' GAAP loss for 9M 2021 was $6.696 million, down 48.5% from $12.99 million in the prior year. Revenue decreased 21.6% to $15.079 million from $19.23 million a year earlier.
Source: {source} pictogram ir.cvsciences.com
Pictogram next
13.08.2021
CV Sciences' GAAP loss for 6M 2021 was $6.657 million, down 32.3% from $9.833 million in the prior year. Revenue decreased 27% to $9.972 million from $13.666 million a year earlier.
Source: {source} pictogram ir.cvsciences.com
Pictogram next
All CV Sciences news
General information
Company nameCV Sciences
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Websitecvsciences.com